✦ LIBER ✦

TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial

✍ Scribed by Sclafani, F.; Gonzalez, D.; Cunningham, D.; Hulkki Wilson, S.; Peckitt, C.; Tabernero, J.; Glimelius, B.; Cervantes, A.; Dewdney, A.; Wotherspoon, A.; Brown, G.; Tait, D.; Oates, J.; Chau, I.

Book ID: 125528172
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 664 KB
Volume: 106
Category: Article
ISSN: 0027-8874
DOI: 10.1093/jnci/dju121

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RAS mutations and cetuximab in locally a

RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial

✍ Sclafani, F.; Gonzalez, D.; Cunningham, D.; Hulkki Wilson, S.; Peckitt, C.; Gira 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 470 KB

PIK3CA, BRAF, and PTEN Status and Benefi

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer--Results from NCIC CTG/AGITG CO.17

✍ Karapetis, C. S.; Jonker, D.; Daneshmand, M.; Hanson, J. E.; O'Callaghan, C. J.; 📂 Article 📅 2013 🏛 American Association for Cancer Research 🌐 English ⚖ 706 KB

762 Prognostic and Predictive Value of T

762 Prognostic and Predictive Value of TP53 Mutations in Node-positive Breast Cancer Patients Treated with Anthracycline-or Anthracycline/taxane Based Adjuvant Therapy – Results From the BIG 02-98 Phase III Trial

✍ M. Olivier; L. Fernández-Cuesta; C. Oakman; E. Quinaux; M.S. Dolci; P.A. Francis 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 71 KB